| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/09/2005 | CN1188405C New Morpholinobenzamide salts |
| 02/09/2005 | CN1188404C Cyclic compound |
| 02/09/2005 | CN1188403C Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/09/2005 | CN1188388C Aminobenzophenones as inhibitors of interleukin and TNF |
| 02/09/2005 | CN1188159C Medicines composition for treating coronary heart disease ventricular premature beat and its prepn |
| 02/09/2005 | CN1188156C Medicine for treating apoplexia hemiplegia |
| 02/09/2005 | CN1188149C Traditional Chinese medicine powder with functions of activating channels, relieving pain, dispelling wind-evil and strengthening-bone |
| 02/09/2005 | CN1188125C Use of 2-imidazoly substituted carbinols for production of medicament for treatment or prophylaxis of disease states as result of ischaemic conditions |
| 02/09/2005 | CN1188121C Therapeutic substituted guanidines |
| 02/09/2005 | CN1188111C Dry powder compositions having improved dispersivity |
| 02/08/2005 | US6852889 Antioxidant nitroxides and nitrones as therapeutic agents |
| 02/08/2005 | US6852751 Difluorobutyric acid metalloprotease inhibitors |
| 02/08/2005 | US6852744 Pyrrolidine derivatives and their use as chymase inhibitor |
| 02/08/2005 | US6852743 Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof |
| 02/08/2005 | US6852742 To modulate the activity of calcium channels, therapy of cardiovascular disease or neurological disorders, that are associated with calcium channels |
| 02/08/2005 | US6852740 Treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I Mitogen-activated protein kinases (MAP) is a family of proline- directed serine/threonine kinases that activate their |
| 02/08/2005 | US6852738 Potent ligands for PPAR gamma and generally have antagonist or partial agonist activity. The compoundsare for treatment, control or prevention of obesity, non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, |
| 02/08/2005 | US6852734 Indole wherein A is an oxygen atom or a nitrogen atom which nitrogen atom is optionally substituted with an alkyl group, and (i) R1 and R2 each stand for a hydrogen atom or an alkyl group, independently, or (ii) R1 and R2 as taken together form |
| 02/08/2005 | US6852732 A tetrahydropyridino or piperidino heterocyclic derivative represented by the formula (I): has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved. (Corticotropin releasing factor |
| 02/08/2005 | US6852731 3-Substituted-7-oxo-4,7-dihydro-thieno(3,2-b)pyridine-6-carboxylic acid benzylamide derivatives; for herpes viruses |
| 02/08/2005 | US6852725 Imidazolyl derivatives |
| 02/08/2005 | US6852724 Administering a sustained release drug dosage-form including >5.0% by weight ranolazine in no more than two tablets per dose to maintain ranolazine plasma levels at a >850 ng base/mL for >24 hours; methacrylic acid copolymer binder |
| 02/08/2005 | US6852717 Inhibit the release of inflammatory cytokines such as interleukin-1 and tumor necrosis factor; for use in therapy of diseases and pathological conditions involving inflammation such as chronic inflammatory disease |
| 02/08/2005 | US6852712 Controlling cell differentiation; antiinflammatory agents |
| 02/08/2005 | US6852518 Glycosyl sulfotransferases GST-4α, GST-4β, and GST-6 |
| 02/08/2005 | CA2112081C Imidazole compounds, their preparation and use |
| 02/08/2005 | CA2097208C The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy |
| 02/03/2005 | WO2005010185A1 Rna capable of inhibiting expression of klf5 gene |
| 02/03/2005 | WO2005010047A2 Antiangiogenic compounds, pharmaceutical composition containing said compounds and the use thereof |
| 02/03/2005 | WO2005009971A1 Quinolone derivative or salt thereof |
| 02/03/2005 | WO2005009968A1 Quinoline derivates and their use in therapy |
| 02/03/2005 | WO2005009942A1 Optically active substituted phenylpropionic acid derivative |
| 02/03/2005 | WO2005009540A1 Perinatal hypoxic-ischemic brain damage treatment |
| 02/03/2005 | WO2005009470A1 Remedy for cardiac failure comprising ask1 inhibitor as the active ingredient and method of screening the same |
| 02/03/2005 | WO2005009445A1 A1 adenosine receptor antagonists |
| 02/03/2005 | WO2005009442A1 Nasal pharmaceutical composition of piribedil |
| 02/03/2005 | WO2005009428A2 Orodispersible pharmaceutical composition of an antithrombotic compound |
| 02/03/2005 | WO2005009419A2 Use of 5-methoxytryptamine as a cardioprotective agents |
| 02/03/2005 | WO2005009343A2 A1 adenosine receptor antogonists |
| 02/03/2005 | WO2005009276A2 Microbial cellulose wound dressing |
| 02/03/2005 | WO2004070018A3 Vegf-b and pdgf modulation of stem cells |
| 02/03/2005 | WO2004009083A8 Antitumor compound and therapeutic uses thereof |
| 02/03/2005 | WO2003106450A8 Phenylaminopyrimidines and their use as rho-kinase inhibitors |
| 02/03/2005 | WO2003094859A3 Epha2 monoclonal antibodies and methods of use thereof |
| 02/03/2005 | WO2003039342A3 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145 |
| 02/03/2005 | WO2002096360A3 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 02/03/2005 | US20050027125 Intensifiers of adenosine receptors for cardiac arrhythmia |
| 02/03/2005 | US20050027121 Heterocyclic carboxy amines such as (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[4-((3S)-3-ethylmorpholino)-2-butynyl]-2-[(1H-indol-3-yl)methyl]piperazine, used as substance P and neurokinin antagonist for prophylaxis of diseases |
| 02/03/2005 | US20050027009 New derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| 02/03/2005 | US20050026990 N-[(3S)-1-hydroxy-2-oxopyrrolidinyl]-N-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-4-sulfonamide or derivatives to treat Respiratory system disorders; arthritis, and bone disorders |
| 02/03/2005 | US20050026989 treatment or prophylaxis of cardiovascular disease, metabolic disease, cancerous disease, or fibrotic disease; arrhythmias, life-threatening cardiac ventricular fibrillation, myocardial infarction, angina pectoris; ischemic states of the heart, diabetes |
| 02/03/2005 | US20050026988 Cyclopenta'b! indole derivatives as spla inhibitors |
| 02/03/2005 | US20050026973 New heterocyclic oxime compounds |
| 02/03/2005 | US20050026969 Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors |
| 02/03/2005 | US20050026967 Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases |
| 02/03/2005 | US20050026956 Carbinols for the treatment of neuropathic dysfunction |
| 02/03/2005 | US20050026945 Cyanoamide compounds useful as malonyl-CoA decarboxylase inhibitors |
| 02/03/2005 | US20050026942 Chemokine receptor binding heterocyclic compounds |
| 02/03/2005 | US20050026941 preferential inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase used for prophylaxis of erectile dysfunction and cardiovascular disorders |
| 02/03/2005 | US20050026935 Compounds |
| 02/03/2005 | US20050026927 Pyrazole derivatives as psychopharmaceuticals |
| 02/03/2005 | US20050026926 N, N'-disubstituted piperazine compounds and their use as analgesics |
| 02/03/2005 | US20050026919 Administering to subject a cyclooxygenase-2 selective inhibitor or an isomer, salt, ester, or prodrug thereof in combination with a cholinergic agent or an isomer, salt, ester, or prodrug thereof; combination therapy for treating a stroke |
| 02/03/2005 | US20050026917 Tricyclic indanyls as integrin inhibitors |
| 02/03/2005 | US20050026915 As melanin concentrating hormone (MCH)receptor antagonists, for prevention or treatment of obesity or eating disorders; (2E)-3-(4-chlorophenyl)-N-[2-(dimethylamino)quinolin-6-yl]prop-2-enamide |
| 02/03/2005 | US20050026908 Can bind to Prostaglandin E2 receptors, especially, EP3 receptor and/or EP4 receptor and show antagonizing activity, and may be useful for prevention and/or treatment of disease, for example, pain, allergy, Alzheimer's disease, cancer |
| 02/03/2005 | US20050026904 Cathepsin S, K, F, L and B reversible inhibitory amidino and guanidino peptidyl compounds useful for treating autoimmune diseases, rheumatoid arthritis, multiple sclerosis, asthma and osteoporosis |
| 02/03/2005 | US20050026875 Treating bacterial, viral, or fungal infections, cancer, a lung injury, an eye disorder, neurological disorder or stroke |
| 02/03/2005 | US20050026863 Delivery of therapeutic gene products by intestinal cell expression |
| 02/03/2005 | US20050026841 Hab18g/cd147 its antagonist and application |
| 02/03/2005 | US20050026840 Protein kinase inhibitors comprising ATP mimetics conjugated to peptides or pertidomimetics |
| 02/03/2005 | US20050026822 Human 3 relaxin |
| 02/03/2005 | US20050026251 Netrin receptor protein for use in identification of modulator for use in treatment and prevention of infection, nervous system, autoimmune, inflammatory, psycological and reproductive disorders |
| 02/03/2005 | US20050026233 Using bioassay for loss-of-function mutations in protein kinase (LKB1) as diagnostic tool in detection of cell proliferative disorders; AMP-activated protein kinase (AMPK) and treatment of diabetic, cardiovascular and dietetic disorders |
| 02/03/2005 | US20050026220 Isolation and mobilization of stem cells expressing vegfr-1 |
| 02/03/2005 | US20050025841 Therapeutic methods using herbal compositions |
| 02/03/2005 | US20050025806 A silicone support of methylvinylsiloxane polymer including a fumed silca reinforcement filler; growth and/or reproduction-associated drug, derivative or analogue and carrier; each implant of insufficient size and/or payload for the predetermined threshold blood level of indicated drug; high-speed |
| 02/03/2005 | US20050025751 Increased or reduced expression of tumor necrosis factors or interleukins; antiinflammatory agents; autoimmune diseases |
| 02/03/2005 | US20050025749 Grafting heart tissue; closure of heart defect |
| 02/03/2005 | CA2533402A1 A1 adenosine receptor antagonists |
| 02/03/2005 | CA2533136A1 Perinatal hypoxic-ischemic brain damage treatment |
| 02/03/2005 | CA2532608A1 Orodispersible pharmaceutical composition of an antithrombotic compound |
| 02/03/2005 | CA2532154A1 Quinoline derivates and their use in therapy |
| 02/03/2005 | CA2531491A1 Agonist polypeptide of receptor for zot and zonulin |
| 02/03/2005 | CA2530352A1 Quinolone derivative or salt thereof |
| 02/03/2005 | CA2524184A1 Microbial cellulose wound dressing comprising phmb |
| 02/02/2005 | EP1502603A1 DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM Fc gamma RIIIa POLYMORPHISM |
| 02/02/2005 | EP1502600A1 Use of botulinum toxin for treating smooth muscle disorders |
| 02/02/2005 | EP1502595A1 An injection made from ixeris sonchifolia for treatment of cardio-cerebral vascular disease and fundus diseases and method of producing thereof |
| 02/02/2005 | EP1502590A1 Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes |
| 02/02/2005 | EP1502109A2 Compositions and methods relating to endothelial cell signaling using the protease activated receptor (par1) |
| 02/02/2005 | EP1501948A1 A dna enzyme to inhibit plasminogen activator inhibitor-1 |
| 02/02/2005 | EP1501936A2 Cytokine protein family |
| 02/02/2005 | EP1501919A1 Soya cell strains with high isoflavone content |
| 02/02/2005 | EP1501857A2 Novel pancortin-pablo protein interactions and methods of use thereof |
| 02/02/2005 | EP1501852A2 Regeneration of endogenous myocardial tissue by induction of neovascularization |
| 02/02/2005 | EP1501838A1 A process for the preparation of clopidogrel |
| 02/02/2005 | EP1501834A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501833A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501830A1 7-aryl-3,9-diazabicyclo[3.3.1]non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases |